๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
HLS Therapeutics Inc. (TSX:HLS)
Canada flag Canada ยท Delayed Price ยท Currency is CAD
3.670
-0.090 (-2.39%)
Nov 19, 2026, 4:00 PM EST
โ† View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

Q3 revenue rose 5% YoY, while cardiovascular sales grew ~21% in local currency and NILEMDO continued to ramp. 2026 Adjusted EBITDA is expected in the lower half of guidance as launch spending and product mix weigh; growth is expected to step up in 2027.

Operator

Good morning, and welcome to the Q3 fiscal 2026 financial results conference call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks.

David Mason
Director of Investor Relations, HLS Therapeutics

Good morning, everyone, and thank you for joining us today. With me on the call are Craig Millian, Chief Executive Officer, John Hanna, Chief Financial Officer, and Brian Walsh, Chief Operating Officer. Earlier this morning, we issued a news release announcing our financial results for the three and nine months ended September 30, 2026. This news release, along with our MD&A and financial statements, is available on our website and on SEDAR+. Please note that slides accompanying today's call can be viewed via the webcast, a link to which is available in our earnings press release and on our website on the Events page. Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results could differ materially from those anticipated.

Risk factors that could affect results are detailed in the company's annual information form, which has been filed on SEDAR+. During the call, we will refer to Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in our press release and annual filings that are available on SEDAR+ and on our website. Please note that all financial information provided is in U.S. dollar unless otherwise specified. I would now like to turn the meeting over to Mr. Millian. Please go ahead.

Craig Millian
CEO, HLS Therapeutics

Thanks, Dave. Good morning, everyone, and thank you for joining us today. On our call today, I will take you through our third quarter performance along with a corporate update. Brian will then follow with a closer look at each of our products. John will cover the financials in detail, and then I will be back with a few closing thoughts before we open it up for questions. Starting with the big picture, the story this quarter is execution in driving our cardiovascular portfolio forward, forging a clear path to accelerated revenue and Adjusted EBITDA growth in 2027 and beyond. Our cardiovascular portfolio delivered third quarter net sales growth of approximately 21% year-over-year in local currency. The NILEMDO launch is on track, with its second full quarter now in the books and with sales starting to ramp.

Private coverage is now fully in effect, and we expect negotiations for public payer coverage to begin this quarter. Strong growth in cardiovascular sales is starting to translate into operating profit, with Adjusted EBITDA up sequentially from Q2 as well as from Q3 last year. We also recently announced an agreement with Bayer that will extend our cardiovascular franchise into heart failure, with HLS leading the commercialization efforts for VERQUVO in Canada starting in the first quarter. At the same time, we remain focused on maintaining our leadership position for Clozaril in Canada, as it continues to generate significant cash flow in both the U.S. and Canada. Along with a strong balance sheet, we have the flexibility to invest in new product launches, pursue business development, and return capital to shareholders. Now, let's briefly review the third quarter financial highlights.

Starting with the top line, revenue in Q3 was $14.2 million, up 5% year-over-year. The cardiovascular portfolio led the way. NILEMDO, in its second full quarter on the market, generated net sales of more than CAD 800,000, up 91% from Q2. VASCEPA third quarter net sales grew approximately 8% in local currency over prior year, with unit demand up 14%. Year-to-date, VASCEPA net sales are up approximately 12% in local currency, and we continue to expect double-digit growth for the full year. Turning to Clozaril, third quarter net sales in Canada were down 2.6% in local currency, while U.S. net sales were in line with the prior year. Adjusted EBITDA for the quarter was $5 million, up slightly from $4.9 million in Q3 last year. This was an improvement following the year-over-year first half decline related to NILEMDO launch investment.

Cardiovascular margins are expanding as NILEMDO ramps, with direct brand contribution from the portfolio of $0.7 million in the quarter. The expanding operating leverage in our cardiovascular business is now beginning to show up in our reported results. Turning to business development. On November 3rd, we announced an agreement with Bayer, under which HLS will assume responsibility for the distribution, promotion, and medical education support of VERQUVO in Canada. VERQUVO is an established medicine approved by Health Canada, commercially available today, with public and private reimbursement already in place. What it has lacked in Canada is promotional focus. That is the opportunity, and it plays to our strengths. The deal structure is capital efficient. We book net sales and pay Bayer a royalty, plus potential commercial milestone payments, while Bayer retains the market authorization and responsibility for regulatory safety and pricing matters.

Our initial OpEx investment will be modest and stage-gated and will scale as the brand gains traction. With activities set to ramp up in the new year, we expect minimal impact on revenue and Adjusted EBITDA in 2027. In the near term, VERQUVO is a modest revenue contributor, and its immediate value is strategic, with more substantial economic benefit coming in later years. VERQUVO extends our cardiovascular franchise into heart failure, and Bayer's choice of HLS is a further vote of confidence in our commercial capabilities. We believe HLS is increasingly seen as an attractive option for pharma companies seeking a partner with proven capabilities and expertise in Canadian specialty therapeutics. Brian Walsh will have more to say on VERQUVO shortly. As we enter our next growth phase, we've also welcomed two new independent directors to our board, Dr. Linda Maxwell and Mark DeLong, who joined on October 1st.

Linda brings scientific expertise and extensive governance experience serving on public pharma company boards. Mark brings deep business development and corporate strategy experience within specialty pharma. That brings me to reiterate our capital allocation priorities. With the heavy lifting of delevering behind us, we are focused first and foremost on investing in growth opportunities while continuing to return capital to shareholders through the buyback. in September, we expanded our normal course issuer bid and remain active in the market. On the growth side, we continue to pursue business development opportunities that fit our criteria. Meanwhile, debt continues to decline through scheduled amortization, lowering our interest expense. Moving to guidance, we are refining our 2026 outlook within previously guided ranges: revenue of $56 million-$60 million and Adjusted EBITDA of $18.5 million-$21 million.

Based on our results to date, we expect revenue to be around the midpoint of the range. For Adjusted EBITDA, we expect to be in the lower half of the guidance range for two reasons. First, given the strength of the NILEMDO launch, we are investing further to drive that momentum into next year. Second, product revenue mix is shifting more rapidly towards the cardiovascular portfolio, where margins are improving but remain lower than Clozaril. Looking ahead, with several potential catalysts and with NILEMDO entering its first full year on the market, we expect a step-up in growth in both consolidated revenue and Adjusted EBITDA in 2027, and then to accelerate further in 2028. Our cardiovascular portfolio will drive that growth, with CV margins expanding as NILEMDO scales, along with the potential launch of NEXLIZET.

Based on our progress to date, we remain confident that the NILEMDO/NEXLIZET peak sales opportunity will be in the range of CAD 50 million-CAD 100 million. In the coming months, we expect greater clarity regarding key catalysts, such as the Health Canada decision on NEXLIZET and the outcome of the pCPA negotiations. As such, we will provide more detailed 2027 guidance with our Q4 results. With that, let me hand things over to Brian.

Brian Walsh
COO, HLS Therapeutics

Thanks, Craig. Good morning, everyone. I will take you through the portfolio this morning, starting with our cardiovascular products, then followed by Clozaril. Before I do, a few words on the Canadian Cardiovascular Congress, which Craig and I attended in Ottawa last month. CCC is the largest annual gathering of cardiovascular specialists from across Canada, and HLS had a strong presence. We supported well-attended educational sessions on the VASCEPA REDUCE-IT trial and on non-statin prevention therapies, including NILEMDO. We also held an advisory board with leading Canadian cardiologists and lipid specialists and launched the CVD Prevention Research Awards with the Canadian Cardiovascular Foundation to support the next generation of Canadian cardiovascular leaders. What stood out to me was the level of engagement, with real enthusiasm for NILEMDO and clear anticipation for NEXLIZET.

For a company of our size, that kind of visibility within the cardiology community matters, and it reinforces our position as a leader in Canadian cardiovascular care. Turning to VASCEPA. Net sales grew approximately 8% in local currency in Q3 year-over-year, and units grew 14%. Year-to-date net sales are up approximately 12% in local currency, and units are up 16%. The underlying demand trend remains strong, with unit growth in the double digits, and we continue to expect double-digit net sales growth for the full year. We are also seeing the synergy we expected from NILEMDO. Our teams are spending more time with the same specialists, and VASCEPA benefits from that time. Now to NILEMDO, which continues to ramp well. Net sales were up 91% over Q2, and the weekly ex-factory run rate strengthened through the quarter.

NILEMDO added another 1,700 new patients in Q3, up to 2,900 since launch. NILEMDO new patients continue to trend at over 3x the number of patients started on VASCEPA during the same period of its launch. However, we are still early in launch, with market access expanding over time. At the end of Q3, approximately one in five of our targeted prescribers had initiated a patient on NILEMDO, demonstrating that we still have significant room to expand prescriber breadth. Most prescribers have only a few patients on NILEMDO so far, so there is considerable room to drive depth as they move from trial to adoption. Our agreements with private payers now cover over 80% of privately insured Canadians. The vast majority of these patients can access NILEMDO as a full benefit without restrictions.

Private coverage ramped through the quarter, and as the remaining agreements with private payers took effect. As a result, we observed a significant step-up in unit demand in September as patients on these newly added plans could fill prescriptions at their pharmacy. Q4 will be our first full quarter with this coverage in effect. This week, we are also launching HLS Assist, a patient support program for our cardiovascular franchise. For eligible patients prescribed VASCEPA or NILEMDO, this program offers reimbursement navigation and co-pay assistance, reducing key barriers to starting and staying on therapy. This is also another example of an operational efficiency where we can scale our investment on a patient support program across multiple products in cardiovascular. On the public reimbursement side, we expect pCPA negotiations to begin this month, and we continue to expect initial provincial listings in the first half of 2027.

That is the next major catalyst for NILEMDO, opening access to the two-thirds of the market covered by public drug plans. On NEXLIZET, the fixed-dose combination of bempedoic acid and ezetimibe, we expect a Health Canada decision by year-end. Assuming an approval, launch would follow in the first half of 2027. NEXLIZET will provide patients the convenience of two key medicines in one daily pill, but importantly, NEXLIZET also strengthens our position in second-line LDL lowering, giving patients who cannot tolerate statins or who need more LDL reduction than their tolerated statin dose provides an important next option. We expect modest additional investment in Q4 and through the first half of 2027 to prepare for the launch, focused on market access, patient support, and targeted promotion. Now to VERQUVO, from both a clinical and a commercial perspective.

Verquvo, or vericiguat, is indicated for adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilized after a recent decompensation event requiring hospitalization or IV diuretic therapy. In plain terms, these are patients coming out of a worsening heart failure event, among the highest-risk patients in cardiovascular medicine. Verquvo's approval is supported by VICTORIA, a phase III outcomes trial in over 5,000 patients. We see Verquvo as an underutilized asset, an oral, once-daily medicine with outcomes data in an area of significant unmet need, consistent with key attributes of the other medicines in our cardiovascular portfolio. Commercially, Verquvo builds on our cardiovascular platform and deepens our relationships with the leaders in Canadian cardiology, which we believe benefits the whole portfolio.

Heart failure is a distinct specialty within cardiology, so our existing medical team will lead our initial effort, focusing on the top tier of heart failure specialists at key centers, and we will begin product training shortly. Our current CV sales team will not initially support Verquvo. We plan to add targeted promotional resources as we see signs of broader adoption. We will be ready to take responsibility for Verquvo in Q1 next year. Now turning to Clozaril. Overall net sales declined slightly in the quarter. In Canada, patient growth is coming from the west, with solid gains in B.C., Alberta, and Saskatchewan. In Quebec, our focus remains retention, and we continue to keep about 97% of patients on branded Clozaril on an annual basis. In Ontario, we are defending our leading market share despite competitive pressures we have described on previous calls.

Nationally, the patient base grew sequentially each month in Q3, an encouraging leading indicator. In the U.S., Q3 net sales were flat year-over-year and down 6.5% year-to-date. When the REMS requirement was eliminated last year, there was some speculation that a less onerous process would expand clozapine prescribing, but we have seen little evidence of that. With fewer barriers, some patients have moved their prescriptions to retail pharmacies, where generic switching is more common. We continue to focus on our specialty pharmacy program, where patients are far more likely to stay on Clozaril. Overall, Clozaril will continue to be an important focus for us as we expect to remain a high-margin, cash-generating business that helps fund growth in other parts of our business. With that, I will turn it over to John for a detailed look at our financials. John?

John Hanna
CFO, HLS Therapeutics

Thank you, Brian, and good morning, everyone. In my section, I will review Q3 results, the balance sheet, and our capital allocation priorities. My comments are all in U.S. dollar, as per our reported numbers, unless otherwise stated. Starting with revenue, total revenue for Q3 was $14.2 million, up 5% from Q3 last year, and $41.7 million year-to-date, up 3%. The Q3 and year-to-date increases were driven by our CV portfolio. Year-to-date, the portfolio grew 19% in local currency, reflecting a 12% increase in VASCEPA net sales and the addition of NILEMDO. Clozaril net sales in Canada were down 2.6% in local currency versus Q3 last year. Clozaril net sales in the U.S. were $2.8 million, in line with Q3 last year. And finally, royalty revenue was $194,000 in Q3 compared to $179,000 in Q3 last year.

Cost of sales in Q3 was up 11% compared to Q3 last year, and up 12% year-to-date, driven by demand growth in VASCEPA and higher NILEMDO volumes. On the expense side, Q3 operating expenses, comprising sales and marketing, medical, regulatory, and patient support, as well as G&A, were $6.4 million, up 6% compared to Q3 last year, and down from $7.2 million in Q2. Year-to-date operating expenses were up 7%, reflecting our investment in the NILEMDO launch. Q3 Adjusted EBITDA was $5 million compared to $4.9 million in Q3 last year, in line with our expectations that margins would improve in the second half of 2026 as the NILEMDO revenue ramps. Year-to-date Adjusted EBITDA was $13.1 million compared to $13.9 million last year. The direct brand contribution from the cardiovascular portfolio was $0.7 million in Q3 after breaking even in the first half of the year.

This is the operating leverage in our cardiovascular business as NILEMDO scales on the commercial infrastructure already in place. More of each incremental sales dollars flows through to Adjusted EBITDA. It is also foundational to growing Adjusted EBITDA in 2027, as Craig mentioned earlier. For Q3, the direct brand contribution from Clozaril to Adjusted EBITDA was $6.3 million and $18.7 million year-to-date. Cash from operations in Q3 was $1.8 million compared to $2.5 million in Q3 last year, while year-to-date cash from operations was $11 million compared to $10.6 million last year, up 4%. Interest expense was $2 million year-to-date compared to $4.3 million in the same period last year, reflecting our 2025 credit agreement and a lower debt balance. This next slide updates our capital generation view. Adjusted EBITDA less royalty revenue less net interest paid on a trailing 12-month basis.

That figure was $15.3 million at the end of Q3, up from $14.7 million at the end of Q2, and $2.3 million at the beginning of 2024. Over the same period, trailing 12-month net interest paid has fallen from as high as $8.8 million- $2.7 million. Turning to capital allocation, our priorities remain unchanged. First, investing in growth. VERQUVO is a good example of what we can do, a partnership structured so that our payments track the brand's commercial success, and one that extends our presence in Canadian cardiovascular medicine. We continue to have the flexibility to act when the right opportunity presents itself. Second, returning capital to shareholders. In September, we expanded our normal course issuer bid to 1.9 million shares. Through to October 31st, we had repurchased more than 1.1 million shares, returning CAD 4.3 million to shareholders.

We continue to believe our shares represent compelling value at current prices. Third, on debt. In Q3, we made a principal repayment of $1.1 million. At September 30th, 2026, the principal balance of our term loans stood at $41.3 million, down 17% from the end of 2025. And net debt stood at $29.9 million, down 22% from the end of 2025. Finally, looking at the balance sheet, cash was $11.4 million at quarter end compared to $11.7 million at the end of 2025. year-to-date, cash from operations of $11 million was largely offset by $7.2 million in debt repayments and $3 million in share repurchases. In summary, the business continues to generate the cash that funds both of our capital priorities, while debt continues to decline through scheduled repayments.

And with our growing cardiovascular business now profitable at the brand level, we are well-positioned to increase revenue and Adjusted EBITDA in 2027. With that, I will pass it back to Craig for his closing comments.

Craig Millian
CEO, HLS Therapeutics

Thanks, John. Before we open it up to Q&A, three quick thoughts on the quarter and where we are headed. First, HLS is in its strongest financial position in years. Our balance sheet is in great shape, we are generating robust cash, and we have expanded our buyback. Second, the growth engine is starting to deliver. The cardiovascular portfolio grew approximately 21% this quarter, the NILEMDO launch is going well, and the cardiovascular portfolio margins are improving. Third, the catalysts heading into 2027 are in focus. Public reimbursement for NILEMDO following pCPA negotiations, a potential NEXLIZET launch in the first half 2027, pending the Health Canada decision, and scaling up physician engagement for VERQUVO starting in Q1, bringing another novel oral medicine into our cardiovascular franchise. 2027 will mark a step-up in growth, and we expect that growth to accelerate into 2028 as these launches ramp.

Our goal is to create shareholder value by building greater scale and increasing operating leverage, both by executing with our current portfolio and through disciplined business development. That concludes my prepared remarks, and we look forward to keeping you updated on our progress. At this point, I will ask our operator to please provide instructions for asking a question.

Operator

Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press star followed by one on your touch-tone phone. Should you wish to decline from the polling process, please press star followed by the two. If you are using a speakerphone, please lift the handset before pressing any keys. We have our first question from Michael Freeman with Raymond James.

Michael Freeman
Analyst, Raymond James

Hey, good morning, team. Congrats on the results. My first question is on NILEMDO. I wonder if you could give us some updated prescription and patient start information through to October, if you can, and discuss how that launch is tracking versus your internal expectations.

Craig Millian
CEO, HLS Therapeutics

Yeah. I will ask Brian maybe to comment on the progress of the launch.

Brian Walsh
COO, HLS Therapeutics

Sure. Hi, Michael. Good morning. Thanks for the question. We saw 1,700 new patient starts in the quarter through end of September, and that is up to 2,900 year-to-date. We are seeing initial early adopters taking up the therapy, with several in their practice, so the focus now remains on expanding prescriber breadth and then deeper into their practice.

Craig Millian
CEO, HLS Therapeutics

Yeah, maybe just comment. As we are into November now, we are not seeing any sign of that slowing down. Into Q4, we are continuing to see that ramp, especially as private coverage in many respects just was kicking in over the summer and into September. We are just starting to see that impact as well in certain geographies where now things are starting to pick up. The question around how that is tracking, it is ahead of what our initial projections were for the year, so we are very pleased with how all these launch KPIs are tracking. As I said in my comments, we have seen nothing to suggest that at this point in the launch, that we are not on track to potentially achieve that peak market opportunity that I laid out of CAD 50 million-CAD 100 million.

Michael Freeman
Analyst, Raymond James

Okay. On that peak market opportunity, what timeframe are you contemplating from the time of launch to achieve sales in that range?

Craig Millian
CEO, HLS Therapeutics

Yeah. Typically, in Canada, peak sales are usually about six to seven years. We'll try to accelerate that as much as possible. But it tends to be staged, obviously, with getting private coverage first, and then next year, as we start to, assuming a positive outcome of our negotiation with pCPA, we'll start to get public listings. That'll be kind of another inflection point in 2027, which will pick up further in 2028. Then as you combine that with the potential launch of NEXLIZET, those are all potential inflection points in terms of growth. We'll start to see really that growth trajectory accelerate, I would say, in the 2027, 2028, even into 2029.

Michael Freeman
Analyst, Raymond James

Gotcha. Okay. Thank you, Craig. If I could throw in one more. On the 2026 EBITDA guidance, you moved expectations down to the lower half of this guidance, and I'm curious how much of this reflects incremental discretionary NILEMDO launch spend versus the lower margin product mix shift that you mentioned in your filings.

Craig Millian
CEO, HLS Therapeutics

Yeah. John, do you want to comment on that?

John Hanna
CFO, HLS Therapeutics

Yeah. I would say, Michael, it is a bit of a combination that order of magnitude, half of it related to spend, half of it related to the product mix. As we noted, U.S. Praluent, a little weaker in the back half of the year than we had originally expected, and that margin extremely, or that product extremely high margin.

Michael Freeman
Analyst, Raymond James

Okay. Thank you very much. I will pass the line.

Operator

We have our next question from David Martin with Bloom Burton.

David Martin
Analyst, Bloom Burton

Hi, good morning. Wondering with NEXLIZET, do you expect that will cannibalize NILEMDO, or will it expand the market?

Craig Millian
CEO, HLS Therapeutics

Yeah, I can maybe make some comments and hand over to Brian. We actually see it as a market expansion opportunity. Obviously, there will be replacement of patients who are on both therapies, so there will be some cannibalization. But we actually see this, David, as an opportunity to maybe move the treatment forward in terms of line of therapy. Rather than going from statin, adding ezetimibe, and then adding NILEMDO, with NEXLIZET available, potentially going straight from statin to the combo product for patients who need additional LDL lowering. And we know the guidelines are all very much heading in the direction of more aggressive LDL-lowering targets. And so NEXLIZET really, as you can see, fits very well within that paradigm. Anything there, Brian?

Brian Walsh
COO, HLS Therapeutics

Yeah, I would agree with that. I think NEXLIZET moves us more strongly into second line, as Craig said, with nearly double the LDL reduction of NILEMDO alone. It also provides the power of combining a moderate-dose statin with NEXLIZET and delivering efficacy that is similar order of magnitude of PCSK9. Even taking patients maybe post-event, coming out of a hospital, being able to discharge on an all-oral regimen.

David Martin
Analyst, Bloom Burton

Okay, great. Flipping over to Clozaril, you mentioned the national patient base grew sequentially in each month of the quarter. Did sales follow the same trend, and did the patient base grow in the full quarter three versus second quarter, and also year-over-year?

Craig Millian
CEO, HLS Therapeutics

I will comment on the patient, and then maybe John can put a finer point on the implications for sales. Our patient volumes have increased sequentially since Q1, which is good news. As we described on the call late last year, we had some competitive pressures specifically in Ontario, which resulted in some decline in patient volume heading into 2027. So year-over-year, our overall patient volume is down, and I think that tracks with some decline in sales as well. But now the good news is that we do have, I think, eight consecutive months of sequential patient growth, but still not quite back to where we were at the peak in 2025. John, anything to add to that?

John Hanna
CFO, HLS Therapeutics

No, I think that captures it. Yeah.

David Martin
Analyst, Bloom Burton

And with the patient growth this year, the sales have been increasing too, in line with the patient growth?

John Hanna
CFO, HLS Therapeutics

I think largely in step.

Brian Walsh
COO, HLS Therapeutics

Yeah.

David Martin
Analyst, Bloom Burton

Okay. And then in Q2-

Craig Millian
CEO, HLS Therapeutics

Sorry, David, I'll just add some commentary to that. It's not quite that simple because bear in mind, the economics are a little bit different within each of the provinces. Depending on where that patient growth comes from, could have implications as far as, for example, gross-to-net. While in general, obviously, as patient volumes increase, that should have a positive effect on sales, it also largely depends on the mix, the geographic mix.

David Martin
Analyst, Bloom Burton

Okay. Then specifically in Ontario, you mentioned on the second quarter call that sales were growing sequentially in Ontario after the drop last year, you had mentioned. Is that still continuing in Q3? Were sales up in Ontario over Q2?

Brian Walsh
COO, HLS Therapeutics

I can speak to, David, to patients. Patients have grown both in Ontario and nationally each month for the last eight months. You'd have to check on sales specifically in Ontario. It's a little lumpier because it's distributed through the hospital, so it's less of a straight line, if you will. But the patient, the underlying indicator is patient growth, and that, as I said, has been consistently growing month over month.

David Martin
Analyst, Bloom Burton

But if there's disconnect between patient growth and sales growth, it's not because your pricing's coming under pressure. It's just stocking and de-stocking and things like that.

Brian Walsh
COO, HLS Therapeutics

Right.

Craig Millian
CEO, HLS Therapeutics

Yeah, that would generally be true, yes. So as Brian said, there's not a smooth order pattern, especially in Ontario, where a lot of order comes through hospitals. Just depending on how much they're stocking and what the cadence of their order patterns are. That's why it's tough to directly correlate in short time frames to directly correlate patient growth with ex-factory sales within a given geography.

David Martin
Analyst, Bloom Burton

Okay, great.

Craig Millian
CEO, HLS Therapeutics

But that's true, that the growth in patient volume should translate into increased sales.

David Martin
Analyst, Bloom Burton

Okay. Thanks, that's it for me.

Craig Millian
CEO, HLS Therapeutics

Yeah.

Operator

As a reminder, if you would like to ask a question, please press star then one. Our next question comes from Justin Keywood with Stifel.

Justin Keywood
Analyst, Stifel

Good morning. Thanks for taking my call. I was hoping to square some of the comments on having the infrastructure to support new growth, but there is also some added investments as well, and then there is the narrowing of the 2026 guidance. My question is if there are new sales reps or if it is other types of investments to support the growth in the portfolio?

Craig Millian
CEO, HLS Therapeutics

Yeah. No, good question, Justin. Yeah, so the spend is not related to any additional infrastructure build. So the footprint is what it is, and we are very confident that that can support the expected growth of NILEMDO and the launch of NEXLIZET moving forward. Certainly in the near to mid-term, there is no expectation to grow our footprint. I think there are certain, and I will ask Brian to comment on some of the specifics, but I think there are just certain OpEx investments in terms of some program spend to support the product. We are talking about hundreds of thousands of dollars here. We are not talking about a massive investment.

What we do not want to do, we are seeing such robust growth heading into next year, having now achieved really strong private reimbursement on the verge, we believe, of getting public reimbursement and potentially also investing in the launch of NEXLIZET pending the Health Canada decision. The last thing we want to do is, for the sake of saving a few hundred thousand dollars, slow down that growth. As I mentioned earlier, our goal, typically peak sales come at six to seven years. Obviously, if there are things we can do to pull that forward, we would like to do that. So, we will, even with the additional investment, the expectation is the profitability of the cardiovascular portfolio will continue to expand each quarter and in a very significant way.

Now, that being said, to answer the other part of the question, the growth in the cardiovascular portfolio is more than offsetting any decline in Clozaril. As John mentioned, the first half of the year, Clozaril sales were down. It is a very high-margin business for us. That shift of growth in cardiovascular at this point, dollar for dollar is not as profitable, obviously, as a decline in Clozaril.

Brian Walsh
COO, HLS Therapeutics

Yeah, sure.

Craig Millian
CEO, HLS Therapeutics

Yeah.

Brian Walsh
COO, HLS Therapeutics

Just to add some color on the spend, Justin, as Craig said, really getting NEXLIZET ready for launch, so doing some work around market access. I described in my remarks the patient support program, which we redesigned to be a portfolio program on an ongoing basis. We will see the leverage in that from a cost perspective, but some small costs there to retool the program. Then, we leaned in on CCC, which was a great opportunity for where we are at in the launch to have some targeted promotion investment around that conference. On the order of a few hundred thousand dollars, as Craig said.

Justin Keywood
Analyst, Stifel

Thank you. That is helpful. Not sure if I missed this, but the VERQUVO in Canada, is there a target peak sales estimate for that product?

Craig Millian
CEO, HLS Therapeutics

Yeah. We've not provided one, but I would say our expectation is that it could do about $5 million-$10 million at peak. It's not obviously the same magnitude as the bempedoic acid franchise, but still one that will be a nice addition. And our expectation is potentially something that will lead to maybe additional opportunities to bring in additional assets, again, within the cardiovascular space beyond where we've traditionally been, which is in the lipid part of cardiovascular. Now we're moving into other parts of cardiovascular medicine. I think both from modest but real potential upside in terms of peak revenue, but also, again, creating some new white space for us to move into.

Justin Keywood
Analyst, Stifel

Understood. Thanks for taking my questions.

Operator

There are no further questions at this time. I will now turn the call over to Craig Millian for closing remarks.

Craig Millian
CEO, HLS Therapeutics

Great. Thank you, Vanessa. And thank you, everyone, for participating on today's call. We look forward to reporting to you on our progress in the coming quarters and speaking with you all again soon. Thanks. Have a great day.

Operator

Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.